0001651308-20-000144.txt : 20200827 0001651308-20-000144.hdr.sgml : 20200827 20200827161611 ACCESSION NUMBER: 0001651308-20-000144 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200827 ITEM INFORMATION: Other Events FILED AS OF DATE: 20200827 DATE AS OF CHANGE: 20200827 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BeiGene, Ltd. CENTRAL INDEX KEY: 0001651308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981209416 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37686 FILM NUMBER: 201143037 BUSINESS ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 BUSINESS PHONE: 13459494123 MAIL ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 8-K 1 bgne-20200827.htm 8-K bgne-20200827
0001651308false00016513082020-08-242020-08-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): August 27, 2020

BEIGENE, LTD.
(Exact Name of Registrant as Specified in Charter)
Cayman Islands
001-37686
98-1209416
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands
(Address of Principal Executive Offices) (Zip Code)
+1 (345) 949-4123
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per shareBGNEThe NASDAQ Global Select Market
Ordinary Shares, par value $0.0001 per share*06160The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o




Item 8.01 Other Events.

On August 27, 2020, BeiGene, Ltd. (the "Company" or "BeiGene") and Singlomics (Beijing DanXu) Biopharmaceuticals Co., Ltd., a biotech company focusing on antibody drug discovery and development utilizing its world-leading single cell sequencing platforms, announced that the companies have executed an exclusive license agreement for BeiGene to develop, manufacture and commercialize globally outside of greater China Singlomics’ investigational anti-COVID-19 antibodies, including DXP-593 and DXP-604. Utilizing high-throughput single-cell sequencing of convalescent blood samples from recovered patients with COVID-19, Singlomics has identified multiple antibodies that have been shown to be highly potent in pre-clinical studies in neutralizing SARS-CoV-2, the virus that causes COVID-19. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.








Item 9.01. Exhibits.
(d) Exhibits.
Exhibit No.Description
99.1Press release issued by BeiGene, Ltd. on August 27, 2020
104The cover page from the Current Report on Form 8-K, formatted in Inline XBRL


Exhibit Index

Exhibit No.Description
99.1
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
 


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 BEIGENE, LTD.
   
   
Date: August 27, 2020By: /s/ Scott A. Samuels        
 Name:Scott A. Samuels
 Title:Senior Vice President, General Counsel



 EX-99.1 2 ex9918-27.htm EX-99.1 Document
Exhibit 99.1
BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals

Phase 1 and Phase 1/2 Clinical Trials Expected to Begin Enrolling Healthy Subjects and Patients with Mild to Moderate COVID-19 by early October

BEIJING, China and CAMBRIDGE, Mass, Aug 27, 2020 – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and Singlomics (Beijing DanXu) Biopharmaceuticals Co., Ltd., today announced that the companies have executed an exclusive license agreement for BeiGene to develop, manufacture and commercialize globally outside of greater China Singlomics’ investigational anti-COVID-19 antibodies, including DXP-593 and DXP-604. Utilizing high-throughput single-cell sequencing of convalescent blood samples from recovered patients with COVID-19, Singlomics has identified multiple antibodies that have been shown to be highly potent in pre-clinical studies in neutralizing SARS-CoV-2, the virus that causes COVID-19.

“Our goal was to find highly potent neutralizing antibodies as quickly as possible in order to develop a potential treatment that can be scaled to treat more patients than convalescent plasma therapy can provide,” said Sunney Xie, Lee Shau-Kee Chair Professor of Peking University, Director of Beijing Advanced Innovation Center for Genomics (ICG), and Co-Founder and Chairman of the Scientific Advisory Board at Singlomics.

“By collaborating with BeiGene, we are confident that these important scientific advancements are in good hands for the next stage of their development, as BeiGene has a strong global clinical development organization with a team of more than 1,300 people as well as the reach and drive to bring innovative treatments to the people who need them,” said Janet Xu Zhang, Ph.D., Co-Founder and CEO at Singlomics.

“Dr. Xie has made an important contribution to our understanding of COVID-19, utilizing single cell genomics to find potentially human neutralizing antibodies," said Lai Wang, Ph.D., Senior Vice President, Head of Global Research, Clinical Operations & Biometrics and APAC Clinical Development, at BeiGene. “We are looking forward to initiating clinical trials for this exciting program and to contribute to the worldwide efforts in developing novel treatments for patients with COVID-19.”

A Phase 1 randomized, double-blind, and placebo-controlled clinical trial is expected to begin enrolling up to 30 healthy subjects in Australia in September. The Phase 1/2 multinational trial in patients with mild to moderate COVID-19 is also expected to begin enrollment by early October. More information on the trials will be available on www.clinicaltrials.gov.

Under the terms of the agreement, Singlomics has granted BeiGene exclusive rights in ex-China territory to develop, manufacture, and commercialize its preclinical assets DXP-593 and DXP-604, as well as for a series of antibody sequences that could target the COVID-19 virus. BeiGene plans to develop one or more of these antibodies globally outside of greater China, while Singlomics will retain rights in greater China. Singlomics will receive an upfront payment and be eligible to receive payments upon the achievement of regulatory and commercial milestones. Singlomics will also be eligible to receive tiered royalties, up to double-digits, on future product sales.

About DXP-593 and DXP-604

DXP-593 and DXP-604 are SARS-CoV-2 neutralizing antibody drug candidates identified by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from over 60 convalescent patients. DXP-593 has exhibited strong neutralization potency in preclinical testing, with an IC50 of 1.2 ng/mL and 15 ng/mL against pseudotyped and authentic SARS-CoV-2, respectively. It displayed strong therapeutic and prophylactic efficacy in SARS-CoV-2-infected rodent models. DXP-604 binds to a different epitope from DXP-593, also with demonstrated high potency. DXP-593 and DXP-604 can potentially be used as a cocktail treatment option that could avoid resistance due to viral mutation.

About Singlomics Biopharmaceuticals

Singlomics (Beijing DanXu) Biopharmaceuticals is a biotech company focusing on antibody drug discovery and development utilizing its world-leading single cell sequencing platforms. It aims to continuously drive innovative drug discoveries for a variety of indications including infectious diseases and auto-immune diseases. Singlomics also plans to build an antibody drug manufacturing facility in Changping, Beijing. It has raised a Series A investment from top healthcare investors in China to continue pushing for portfolio expansion and CMC manufacturing facility construction.


Exhibit 99.1
About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

BeiGene’s Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding future development and potential commercialization of the licensed product candidates; potential payments to Singlomics; the potential of the licensed product candidates; and the parties’ commitments and the potential benefits of the collaboration. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on the Company’s clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

Singlomics Contacts

Janet Xu Zhang
ir@singlomics.com

BeiGene Contacts

Investors Contact
Craig West
(857) 302-5189
ir@beigene.com

Media Contact
Liza Heapes or Vivian Ni
(857) 302-5663 or (857) 302-7596
media@beigene.com

 EX-101.SCH 3 bgne-20200827.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 bgne-20200827_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 bgne-20200827_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 bgne-20200827_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Entities [Table] Entities [Table] Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three City Area Code City Area Code Cover [Abstract] Cover [Abstract] Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Document Type Document Type Entity Addresses [Line Items] Entity Addresses [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Trading Symbol Trading Symbol Document Period End Date Document Period End Date Entity Information [Line Items] Entity Information [Line Items] Entity Registrant Name Entity Registrant Name Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Country Entity Address, Country Entity Addresses [Table] Entity Addresses [Table] Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer EX-101.PRE 7 bgne-20200827_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 bgne-20200827_htm.xml IDEA: XBRL DOCUMENT 0001651308 2020-08-24 2020-08-25 0001651308 false 8-K 2020-08-27 BEIGENE, LTD. E9 001-37686 98-1209416 c/o Mourant Governance Services (Cayman) Limited 4 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 KY (345) 949-4123 false false false false American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share BGNE NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information Document
Aug. 25, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 27, 2020
Entity Registrant Name BEIGENE, LTD.
Entity Central Index Key 0001651308
Amendment Flag false
Entity Incorporation, State or Country Code E9
Entity File Number 001-37686
Entity Tax Identification Number 98-1209416
Entity Address, Address Line One c/o Mourant Governance Services (Cayman) Limited
Entity Address, Address Line Two 4 Solaris Avenue, Camana Bay
Entity Address, City or Town Grand Cayman
Entity Address, Postal Zip Code KY1-1108
City Area Code (345)
Entity Address, Country KY
Local Phone Number 949-4123
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
Trading Symbol BGNE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Information [Line Items]  
Entity Registrant Name BEIGENE, LTD.
Document Period End Date Aug. 27, 2020
Entity Address, Address Line One c/o Mourant Governance Services (Cayman) Limited
Entity Address, Address Line Two 4 Solaris Avenue, Camana Bay
Entity Address, City or Town Grand Cayman
Entity Address, Postal Zip Code KY1-1108
Entity Address, Country KY
City Area Code (345)
Local Phone Number 949-4123
Pre-commencement Issuer Tender Offer false
Entity Addresses [Line Items]  
Entity Address, City or Town Grand Cayman
Entity Address, Address Line Three
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:GH_ 0 / ( \ !X;"]W;W)K8F]O:RYX;6R-49:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M# MV743&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$ MP,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/ M73>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0 ( M 6"&U$D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_ M[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ M0=@S9)[NF:*'3^ 5!+ P04 M " %@AM199!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RM MDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C> MO,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0 MP1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH% M.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D M(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S6 M3AI_YHOA/UY_ 5!+ 0(4 Q0 ( 6"&U$'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ !8(;42/" M1ZON *P( !$ ( !KP &1O8U!R;W!S+V-O&UL M4$L! A0#% @ !8(;49E&PO=V]R:W-H965T&UL M4$L! A0#% @ !8(;48.II0/4 0 ,@8 T ( !O@T M 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! M A0#% @ !8(;420>FZ*M ^ $ !H ( !$A( 'AL M+U]R96QS+W=O9(9 M 0 SP, !, ( !]Q( %M#;VYT96YT7U1Y<&5S72YX;6Q0 52P4& D "0 ^ @ 010 end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Document Sheet http://beigene.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports bgne-20200827.htm bgne-20200827.xsd bgne-20200827_cal.xml bgne-20200827_def.xml bgne-20200827_lab.xml bgne-20200827_pre.xml ex9918-27.htm http://xbrl.sec.gov/dei/2019-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bgne-20200827.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "bgne-20200827_cal.xml" ] }, "definitionLink": { "local": [ "bgne-20200827_def.xml" ] }, "inline": { "local": [ "bgne-20200827.htm" ] }, "labelLink": { "local": [ "bgne-20200827_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bgne-20200827_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bgne-20200827.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bgne", "nsuri": "http://beigene.com/20200827", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bgne-20200827.htm", "contextRef": "ifb1344e35a07424f91933afcbe6dfb3b_D20200824-20200825", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information Document", "role": "http://beigene.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bgne-20200827.htm", "contextRef": "ifb1344e35a07424f91933afcbe6dfb3b_D20200824-20200825", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]", "terseLabel": "Entity Addresses [Line Items]" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]", "terseLabel": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001651308-20-000144-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001651308-20-000144-xbrl.zip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